spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Chiltern Acquires Japanese Clinical Research Organization Integrated Development Associates Co. Ltd.

Chiltern

Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

London, U.K., Wilmington, N.C. and Tokyo, Japan; May 31, 2017 (Business Wire)Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

With staff based in Japan, Korea and Southeast Asia, IDA has extensive expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will allow Chiltern to offer optimal approaches for integrating Japan and Asia into global drug development. In addition, the acquisition opens opportunities for Japanese companies to enter a wider market by relying on Chiltern’s global expertise and connections. 

“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” said Jim Esinhart, Ph.D., Chiltern CEO. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”

IDA will do business as a wholly owned subsidiary of Chiltern and be renamed IDA, a Chiltern Company. As a part of this agreement, IDA’s founder and CEO, John Winebarger, will continue to lead IDA. Winebarger has more than 30 years’ experience working in Japan and will join Chiltern’s leadership team.

To learn more about Chiltern’s global clinical development services, visit Chiltern.com.

About Chiltern

Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.
phone UK:+44(0)1753 512 000; US:+1 (423) 968 9533
email info@chiltern.com
web www.chiltern.com
email UK: 171 Bath Road, Slough, Berkshire, SL1 4AA. US: 3147 S. 17th Street, Suite 300 Wilmington, NC 28412.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PCI’s Tredegar Site Announces Significant Expansion of Analytical Laboratories at its Center of Excellence for Contained Manufacturing

Philadelphia, USA- March 19, 2018. Global pharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce a laboratory expansion at its site in Tredegar, Wales, UK. 
More info >>


White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

Industry Events

Symposium on Digitalization and Big Data in Biotech and Pharma

6 June 2018, ETH Zurich, Institute for Chemical and Bioengineering, Vladimir-Prelog-Weg 1

The Symposium on Digitalization and Big Data in Biotech & Pharma will bring together experts and key stakeholders from industry and academia to discuss and current digital innovations and technological trends in the pharmaceutical sector.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement